CDH1 and carcinoma: E-cadherin is known to suppress tumor cell invasion, and the re-expression of E-cadherin in E-cadherin-deficient carcinomas reverts cells to a less invasive, less aggressive phenotype [19]–[21], while the loss of E-cadherin is associated with ovarian cancer metastasis, peritoneal dissemination, and poor prognosis [22]–[26].